Community-Acquired Pneumonia Treatment Guidelines

Introduction to Community-Acquired Pneumonia

The American Thoracic Society recommends amoxicillin 1g three times daily as the preferred first-line agent for outpatients without comorbidities, with macrolides or doxycycline as alternatives for penicillin-allergic patients 1
The American Thoracic Society suggests that amoxicillin monotherapy is appropriate when local pneumococcal resistance to macrolides is <25% 1

The American College of Chest Physicians recommends macrolide alternatives, including azithromycin 500mg on day 1 then 250mg daily, or clarithromycin 500mg twice daily 1
The Infectious Diseases Society of America recommends doxycycline 100mg twice daily as another option for penicillin-allergic patients 1

The British Thoracic Society recommends combined oral therapy with amoxicillin and a macrolide for hospitalized patients with non-severe community-acquired pneumonia 2
The British Thoracic Society suggests that most hospitalized patients can be adequately treated with oral antibiotics rather than IV formulations 2

The British Thoracic Society recommends immediate parenteral antibiotics with an IV beta-lactam combined with a macrolide for patients with severe pneumonia 2
The British Thoracic Society suggests that IV combination therapy should be initiated immediately after diagnosis 2

The Infectious Diseases Society of America recommends piperacillin-tazobactam 4.5g IV every 6 hours as the first-line backbone agent for hospital-acquired and ventilator-associated pneumonia, with additional agents added based on mortality and MRSA risk factors 3, 4
The Society for Healthcare Epidemiology of America recommends a risk stratification framework to guide treatment, including high mortality risk factors such as need for ventilatory support and septic shock at presentation 3, 4

The Infectious Diseases Society of America recommends piperacillin-tazobactam 4.5g IV every 6 hours as the first-line antibiotic for aspiration pneumonia, providing necessary anaerobic coverage inherent to this condition 3
The Society for Healthcare Epidemiology of America suggests that the same risk stratification and treatment algorithm applies as for hospital-acquired pneumonia 3

The Infectious Diseases Society of America recommends narrowing antibiotic spectrum based on susceptibilities to reduce C. difficile risk, adverse effects, and resistance development once culture results return 4
The Society for Healthcare Epidemiology of America suggests that if MRSA was covered empirically but not isolated, vancomycin or linezolid should be discontinued 4

Piperacillin‑tazobactam provides complete coverage for the typical pathogens of skin, soft‑tissue, and bone infections—including methicillin‑susceptible Staphylococcus aureus (MSSA)—making additional cefazolin unnecessary when it is added for hospital‑acquired pneumonia (HAP). 5
Maintaining cefazolin together with piperacillin‑tazobactam creates redundant MSSA coverage without any clinical benefit. [6][5]
Redundant β‑lactam therapy increases the risk of toxicity, drug‑drug interactions, and antimicrobial resistance without improving patient outcomes. 7

The Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) recommend piperacillin‑tazobactam 4.5 g IV every 6 hours as the preferred backbone agent for HAP and ventilator‑associated pneumonia. 5
This dosing regimen ensures the necessary antipseudomonal activity required for nosocomial respiratory infections. 5

Patients without MRSA risk factors (no recent IV antibiotics, unit MRSA prevalence < 20 %): discontinue cefazolin and continue piperacillin‑tazobactam alone; this regimen covers both the respiratory infection and the concurrent skin/bone infection. [6][5]
Patients with MRSA risk factors (recent IV antibiotics, high unit MRSA prevalence, prior MRSA isolation): discontinue cefazolin, add vancomycin or linezolid for MRSA coverage, and maintain piperacillin‑tazobactam for the broader spectrum. [6][5]

In patients with a high risk of mortality (e.g., requiring ventilatory support or septic shock), consider adding a second antipseudomonal agent—such as ciprofloxacin or an aminoglycoside—to piperacillin‑tazobactam. 5
MRSA coverage (vancomycin or linezolid) should still be added if MRSA risk factors are present. 5

For confirmed MSSA osteomyelitis, once susceptibility results are available, transition to cefazolin as directed therapy to complete the prolonged treatment course. 6
During the acute empirical phase when HAP co‑exists, piperacillin‑tazobactam alone provides sufficient coverage for both the pneumonia and the bone infection. 5
After culture data clarify the pathogen profile, de‑escalate therapy (e.g., discontinue vancomycin/linezolid if MRSA is not isolated, switch to cefazolin for MSSA) to reduce the risk of Clostridioides difficile infection, adverse effects, and resistance development. 6